Deep vein thrombosis and malignancy: a surgical oncologist's perspective

Area of Science:

• Oncology
• Hematology
• Vascular Medicine

Background:

• Oncology patients have an elevated risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Risk factors include malignancy, comorbidities, and cancer therapies.
• Venous thromboembolism (VTE) presents unique challenges in cancer patients.

Purpose of the Study:

• To discuss specific issues of venous thrombosis in oncology.
• To review screening, prophylaxis, and treatment strategies for VTE in cancer patients.
• To highlight the anti-neoplastic effects of heparin and ethnic variations in DVT incidence.

Main Methods:

• MEDLINE search of the English literature.
• Review of clinical considerations for VTE in cancer.
• Analysis of risk factors and management guidelines.

Main Results:

• Screening for malignancy in idiopathic DVT is necessary.
• A high index of suspicion for VTE is crucial in cancer patients.
• Prophylaxis varies: elastic compression stockings and early mobilization for non-major surgery patients; low-molecular-weight heparin for major surgery.
• Heparin may have anti-neoplastic effects.
• Asian patients show a lower DVT incidence than Caucasians.
• VTE treatment palliates symptoms in advanced malignancy, often requiring long-term anticoagulation with warfarin.

Conclusions:

• VTE management in oncology requires tailored prophylaxis based on malignancy type and surgical intervention.
• Early detection and appropriate anticoagulation are vital for managing DVT and PE in cancer patients.
• Further research into heparin's anti-neoplastic properties and ethnic variations in VTE risk is warranted.